Howard G. Welgus - 01 Oct 2025 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role
Director
Signature
/s/ Latha Vairavan, as Attorney-in-Fact for Howard G. Welgus
Issuer symbol
ARQT
Transactions as of
01 Oct 2025
Transactions value $
-$173,197
Form type
4
Date filed
03 Oct 2025, 17:01
Previous filing
04 Sep 2025
Next filing
05 Nov 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Welgus Howard G. Director C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE /s/ Latha Vairavan, as Attorney-in-Fact for Howard G. Welgus 2025-10-03 0001801050

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARQT Common Stock Options Exercise $16K +9.54K +9.52% $1.68 110K 01 Oct 2025 Direct F1
transaction ARQT Common Stock Sale -$180K -9.54K -8.69% $18.92 100K 01 Oct 2025 Direct F1, F2
transaction ARQT Common Stock Sale -$8.74K -462 -0.46% $18.92 99.7K 01 Oct 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARQT Stock Option (right to buy) Options Exercise $0 -9.54K -100% $0.00 0 01 Oct 2025 Common Stock 9.54K $1.68 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026.
F2 The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $18.84 to $19.038, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 This option is fully vested.